Search Results
The product title you are looking for is no longer available. Other similar products that may interest you are listed below:
 |
Results for 'Dainippon Sumitomo' |
| Title | Publication Date | Price | Relevance |
|---|---|---|---|
|
Dainippon Sumitomo Pharma Co., Ltd Pharmavitae Profile |
December 2007 | £1980 | 100 % |
|
Dainippon Sumitomo Pharma Co. Ltd: PharmaVitae Model |
January 2009 | £1990 | 97 % |
|
Dainippon Sumitomo Pharma Co., Ltd. -Company Report |
February 2008 | £250 | 97 % |
|
Dainippon Sumitomo Pharma Co Ltd Deals Briefing Partneringdesk |
June 2006 | £215 | 97 % |
|
Dainippon Sumitomo Pharma Co., Ltd.-Company Report |
January 2010 | £495 | 97 % |
|
Partnering Agreements with Dainippon Sumitomo 2010 |
January 2010 | £295 | 97 % |
|
Dainippon Sumitomo: Pipeline, Products, Performance, Potential |
January 2010 | £595 | 96 % |
|
Dainippon Sumitomo Pharma Co., Ltd. - Financial and Strategic Analysis Review |
July 2009 | £83 | 95 % |
|
Dainippon Sumitomo Pharma Co., Ltd. - SWOT Analysis |
January 2009 | £44 | 35 % |
|
Pharmaceutical Regulatory Affairs in The Eu & US |
January 2006 | £1095 | 24.5 % |
|
Ono: Pipeline Products Performance Potential |
November 2008 | £595 | 23.5 % |
|
MedImmune Deals Briefing Partneringdesk |
June 2006 | £215 | 18.9 % |
|
The True State of the Pharmaceutical Industry |
December 2008 | £495 | 16 % |
|
Japanese Pharmaceutical Market, 2006-2011 |
January 2006 | £1499 | 15.5 % |
|
Pharma R&D Fact Book, The 2006 |
November 2007 | £495 | 13.5 % |
|
Kyowa Hakko Pipeline Products Performance Potential |
July 2008 | £595 | 13 % |
|
Takeda: Pipeline, Products,Performance,Potential |
November 2009 | £595 | 12.5 % |
|
Mitsubishi Pharma: Pipeline, Products, Performance, Potential |
October 2007 | £595 | 11 % |
|
Global Image Dermatology Drug Market, 2005-2012, The High-Growth Opportunities in Aesthetic Medicine |
November 2005 | £795 | 10 % |
|
Eisai: Pipeline, Products, Performance, Potential |
November 2009 | £595 | 10 % |
|
Pharmaceutical Distribution in Europe The Emergence of Direct-to-Pharmacy Supply |
February 2008 | £995 | 10 % |
|
Peroxisome Proliferator-Activated Receptor (PPAR) Agonists Competitor Analysis |
November 2008 | £270 | 7.7 % |
|
Enzyme Replacement & Enhancement Therapies (ERT) Competitor Analysis |
November 2008 | £225 | 7.7 % |
|
Bipolar Disorder Drug Pipeline Analysis and Market Forecasts to 2015 |
December 2009 | £1320 | 7.35 % |
|
Partnering Agreements with Bigpharma |
February 2010 | £1395 | 6.65 % |
|
Pharmaceutical Companies Performance Tables 2005 |
November 2006 | £295 | 6.3 % |
|
Emerging Diabetes Drugs Competitor Analysis |
November 2008 | £540 | 5.25 % |
|
Bigpharma Dealmaking and Agreements Handbook 2007 Companies, Contacts & Partnering Agreements |
September 2007 | £1195 | 5.25 % |
|
Bigpharma Agreements Handbook Partnering Agreements |
September 2008 | £1195 | 5.25 % |
|
Bigpharma Partnering Agreements |
March 2008 | £1195 | 5.25 % |
|
Gilead Sciences Performance, Products, Pipeline and Potential |
February 2008 | £595 | 4.9 % |
|
Generics in Japan |
November 2009 | £1825 | 4.9 % |
|
AstraZeneca: Pipeline, Products, Performance, Potential |
November 2007 | £595 | 4.2 % |
|
Bigpharma Dealmaking Handbook Companies & Contacts |
September 2008 | £1195 | 4.2 % |
|
Bristol-Myers Squibb Pipeline, Products, Performance, Potential |
February 2008 | £595 | 3.85 % |
|
World Gastrointestinal Disorders Market 2006-2011; The |
January 2006 | £1799 | 3.85 % |
|
Oncology Partnering Agreements in Pharma, Biotech and Diagnostics |
June 2009 | £1195 | 3.85 % |
|
New Drug Futures: Central Nervous System Chapter |
May 2006 | £695 | 3.85 % |
|
Astellas Pharma: Pipeline, Products, Performance, Potential |
November 2007 | £595 | 3.5 % |
|
Eisai Pipeline - Products - Performance - Potential |
June 2008 | £595 | 3.5 % |
|
Drug Delivery Partnering Agreements In Pharma & Biotech |
October 2009 | £1195 | 3.5 % |
|
Pipeline Insight: Schizophrenia |
July 2006 | £4180 | 3.15 % |
|
The Japanese Pharmaceutical Market Outlook to 2014 Policy environment, market structure, competitive landscape, growth opportunities |
January 2010 | £3835 | 3.15 % |
|
Clinical Stage Partnering Agreements in Biopharma |
June 2008 | £1195 | 3.15 % |
|
AstraZeneca Pharmaceuticals, Company Profile and Healthcare |
June 2008 | £595 | 3.15 % |
|
Leukemia A Competitive Analysis to New Products, Portfolio Planning, Licensing & Acquisition Through Pipeline Benchmarking |
April 2009 | £1745 | 3.15 % |
|
Manufacturing & Supply Agreements in Pharma, Biotech and Diagnostics 2nd Edition |
July 2009 | £1195 | 3.15 % |
|
Lymphoma Drug Development Strategies at Work |
June 2009 | £1745 | 3.15 % |
|
Gastrointestinal Disorders Market Intelligence to 2012 |
May 2007 | £1499 | 3.15 % |
|
The Future of the Home Healthcare Equipment Market to 2016 Market Forecasts, Competitive Landscape and Pipeline Analysis |
March 2010 | £2310 | 2.8 % |
|
Diabetes Drug Pipeline Competitor Analysis |
November 2008 | £1075 | 2.8 % |
|
Animal Pharm's Top Tier Companies 2007 edition |
January 2007 | £895 | 2.8 % |
|
The Antipsychotics Market Insight & Analysis 2008 |
February 2008 | £1499 | 2.8 % |
|
Antipsychotics Market Insight & Analysis 2008 |
February 2008 | £1499 | 2.8 % |
|
CNS Drug Discoveries What the Future Holds |
November 2006 | £1995 | 2.8 % |
|
CNS Therapeutics A World Market Review |
November 2009 | £1980 | 2.45 % |
|
Competitive Outlook of Cancer Drug Development The Missing Handbook to New Product Planning and Portfolio Planning |
August 2009 | £2195 | 2.45 % |
|
Animal Pharm's Top 20 2006 edition |
January 2006 | £795 | 2.45 % |
|
Sanofi-aventis Pipeline, Products,Performance,Potential |
September 2007 | £249 | 2.45 % |
|
Partnering Agreements In Diagnostics Trends in diagnostics partnering deals |
September 2009 | £1195 | 2.45 % |
|
World Neurodegenerative Diseases Market 2009-2024 |
September 2009 | £1499 | 2.1 % |
|
Japanese Pharmaceutical Market 2008-2023, the |
October 2008 | £1499 | 2.1 % |
|
M&A trends in Pharma |
October 2008 | £3965 | 2.1 % |
|
Global Cardiovascular Drugs Market 2009-2024 |
June 2009 | £1499 | 2.1 % |
|
Global Diabetes Market; The Therapeutics, Diagnostics and Complications |
August 2006 | £1650 | 1.75 % |
|
Pipeline and Commercial Insight: Schizophrenia - Second generation depots protect market value |
October 2008 | £5285 | 1.75 % |
|
Pfizer Market Outlook for a Global Leader, 2008-2013 |
August 2008 | £1499 | 1.75 % |
|
Parkinson's Disease Market analysis and forecasts 2008-2012, 2017 & 2022 |
January 2008 | £1499 | 1.4 % |
|
Monoclonal Antibody Therapeutics 2009-2024 |
August 2009 | £1499 | 1.4 % |
|
The World Antibacterial Treatments Market 2010-2024 |
December 2009 | £1499 | 1.4 % |
